The Microarray Shared Resource was created in 1999 to support Mayo Cancer Center Investigators needs for global transcriptional profiling. The major services provided include gene-expression profiling using Affymetrix GeneChips, and verification of expression levels by real-time PCR methods, and quality assessment procedures for RNA. Data analysis has been added as a service in 2003. Services available on a custom basis include custom spotting of oligonucleotide and cDNA microarrays, and hybridization and analysis of BAC assays. Since 2000, the Microarray Shared Resource has supported experiments from over 50 MCCC Investigators. In 2002, investigators from 6 Cancer Center Programs utilized this Shared Resource. Greatest usage in 2002 and 2003 has been from members of the Prostate Cancer and Hematologic Malignancies Programs. The goals for the Microarray Shared Resource are to bring state-of the art improvements in genomics approaches to research in oncology. This includes: i. increasing the sensitivity and specificity of gene-expression profiling experiments by routinely using laser-captured micro-dissected tissues; ii. assessing feasibility of utilizing paraffin-embedded materials; iii. improving the sensitivity of transcriptional profiling for low copy-number transcripts using oligonucleotide microarrays; iv. analysis of small chromosome regions with custom-fabricated BAC microarrays; v. expanding data analysis capacity and sophistication.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-31
Application #
7125537
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
31
Fiscal Year
2005
Total Cost
$124,201
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898

Showing the most recent 10 out of 1129 publications